在欧洲心脏病学学会专题讨论会上,Catheter Precision的VVO技术在确定VT来源时显示了90%的准确性。 Catheter Precision's VIVO technology demonstrated 90% accuracy in identifying VT origin at the European Society of Cardiology Symposium.

Catheter Precision， Inc. 在欧洲心脏病学会研讨会上展示了有希望的中期结果，展示了其用于确定疤痕相关折返性 VT 患者室性心动过速 （VT） 起源的 VIVO 技术。 Catheter Precision, Inc. presented promising interim results at the European Society of Cardiology Symposium, showcasing its VIVO technology for identifying the origin of ventricular tachycardia (VT) in patients with scar-related re-entrant VT. 华威医学院正在进行的研究表明,与侵入性测绘相比,准确率为90%,在7个月后的程序成功率为90%. The ongoing study at Warwick Medical School demonstrated a 90% accuracy rate compared to invasive mapping, with a procedural success rate of 90% at seven months. 维沃已获得FDA的批准, 旨在提高美国的患者护理. VIVO has received FDA clearance and aims to enhance patient care in the U.S.